medigraphic.com
ISSN 0188-2198 (Print)

2012, Number 2

<< Back Next >>

Rev Mex Cardiol 2012; 23 (2)

Homocysteine (HCY), uric acid and their relationship with HDL in patients with coronary artery disease

Contreras-Zárate M, Contreras-Zárate JI, Gómez–García A, Cruz-Balandrán J, Rodea-Hernández SR

Language: Spanish
References: 27
Page: 58-63
PDF size: 86.17 Kb.


ABSTRACT

Introduction: Coronary heart disease (CHD) is the main cause of death in Mexico. Homocisteine (HCY), uric acid (UA) and cholesterol (c-HDL) are known independent factors for cardiovascular disease. Objective: To investigate the relationship between HCY, UA and c-HDL in patients with Coronary Heart Disease (CHD). Material and methods: Comparative cross-sectional study in 75 patients with CHD, without diuretics, allopurinol, folic acid, B complex and without kidney or thyroid disease. To each patient was collected a fasting blood sample for quantification of HCY, UA, glucose and lipid profile. The statistical analysis was realized in SPSS V18. Results: Mean age was 60.96 ± 16.22 years. 58.45% had type 2 diabetes and/or hypertension. Patients were divides in 2 groups: UA ≥ 7 mg/dL y UA ‹ 7 mg/dL. We found differences in HCY, c-HDL, systolic and diastolic blood pressure (p ‹ 0.005). The UA correlated with c-HDL(r = -0.307, p = 0.010) and HCY with c-HDL (r = -0.283, p = 0.019). In the linear regression analysis was found to HCY as predictor of UA (standardized coefficient β:0.294, t:2.458, p = 0.017) and c-HDL (standardized coefficient β:0.269, t:2.232, p = 0.029). Conclusions: There is relationship between HCY, UA with c-HDL and c-HDL. HCY is a predictor of hyperuricemia, low c-HDL levels in patients with CHD. It is recommended to include the determination of HCY as routine in patients with a family history of CHD.


REFERENCES

  1. Chilton RJ. Pathophysiology of coronary heart disease. JAMA 2004; 104: S5-S8.

  2. Álvarez AC, Leyva-Jiménez R, Gómez-García A. Relación entre la hiperhomocisteinemia y la insuficiencia renal crónica. Ciencia Nicolaita 2005; 40: 77-90.

  3. Stampter MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 887-889.

  4. Clarke R, Daly L, Robinson K, Naughten E et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155.

  5. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-1057.

  6. Heijer M, Hoster T, Blom JH, Bos MJ et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.

  7. Willinek WA, Ludwing M, Lennarz M, Holler T, Stumpe OK. High-normal serum homocysteine concentrations are associated with an increased risk of early atherosclerosis carotid artery wall lesions in healthy subjects. J Hypertens 2000; 8: 425-430.

  8. Niggard O, Vollset SE, Refsum H, Stevensvold I et al. Total plasma homocysteine and cardiovascular risk profile. JAMA 1995; 274: 1526-1533.

  9. Verhoef P, Hennekens CH, Allen RH et al. Plasma total Homocysteine and a risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol 1997; 79: 799-805.

  10. Nyggard O, Nordrehaug JE, Refsum H et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-235.

  11. Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115: 2526-2532.

  12. Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 2001; 87: 1411-1414.

  13. Letho S Niskanen L, Rönnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998; 29: 635-639.

  14. Schretlen DJ, Inscore AB, Vannorsdall TD et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; 69: 1418-1423.

  15. Roberts JM, Bodnar LM, Lain KY et al. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension 2005; 46: 1263-1269.

  16. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59.

  17. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007; 27: 435-440.

  18. Navarro LF. Bases genéticas de la enfermedad coronaria. Rev Esp Cardiol 2002; 55: 413-431.

  19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL; and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289: 2560-2572.

  20. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection Evaluation and treatment of high blood cholesterol in adult (Adult Treatment Panel III) final report. Circulation 2002; 106: 343-421.

  21. Feig DI, Kang DH, Johnson RJ. Ácido úrico y riesgo cardiovascular. N Engl J Med 2008; 359: 1811-1821.

  22. Cuneo C. Lipoproteínas de alta densidad y enfermedad coronaria. Rev Fed Arg Cardiol 2001; 30: 103-111.

  23. Kwiterovich PO Jr. The antiatherogenic role of high-density lipoprotein colesterol. Am J Cardiol 1998; 82: 13Q-21Q.

  24. Xiao Y, Zhang Y, Lv X, Su D et al. Relationship between lipid profiles and plasma total homocysteine, cysteine and the risk of coronary artery disease in coronary angiographic subjects. Lipid Health Dis 2011; 10: 137-142.

  25. Soinio M, Marniemi J, Laakso M, Letho S, Rönnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 2004; 140: 94-100.

  26. Kannani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation 1997; 95: 1119-1121.

  27. Saavedra WF, Paolocci N, St John ME et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002; 90: 297-304.




2020     |     www.medigraphic.com